Research indicates that EBV infection tends to occur before tumor formation, and the immune marker CD21 on FDC is identified as the receptor for EBV, suggesting a pivotal role for EBV in the process of tumor development [3, 6, 7,]. The gene discussed is CR2; the disease is Epstein-Barr virus infection.